An HLA-modified ovarian cancer cell line induced CTL responses specific to an epitope derived from claudin-1 presented by HLA-A*24:02 molecules
Autor: | Mitsugu Fujita, Fumitaka Kikkawa, Yasushi Uemura, Ayako Demachi-Okamura, Kiyosumi Shibata, Hiroyuki Maki, Yoshiki Akatsuka, Eiko Yamamoto, Shinji Kondo, Kiyotaka Kuzushima, Tomoya Hirosawa, Kazuhiko Ino |
---|---|
Rok vydání: | 2013 |
Předmět: |
Adult
Cytotoxicity Immunologic Immunology Clone (cell biology) Epitopes T-Lymphocyte HLA-A24 Antigen Respiratory Mucosa Human leukocyte antigen Biology Lymphocyte Activation Epitope Cell Line Tumor Claudin-1 Humans Immunology and Allergy Cytotoxic T cell Transgenes Ovarian Neoplasms CDNA Library Construction General Medicine Molecular biology Peptide Fragments Clone Cells CTL Cancer cell Expression cloning Female Adenocarcinoma Clear Cell T-Lymphocytes Cytotoxic |
Zdroj: | Human Immunology. 74:1103-1110 |
ISSN: | 0198-8859 |
DOI: | 10.1016/j.humimm.2013.06.030 |
Popis: | In an attempt to induce cytotoxic T lymphocytes (CTLs) that react to ovarian cancer cells, we isolated a CTL clone that specifically recognizes claudin-1 in an HLA-A*24:02-restricted manner. Naïve CD8(+) T lymphocytes were obtained from a healthy adult donor and stimulated twice in vitro with HLA-modified TOV21G cells that were originally derived from an ovarian clear-cell carcinoma line. The TOV21G modification involved RNAi-mediated gene silencing of intrinsic HLA molecules and lentiviral transduction of a synonymously mutated HLA-A*24:02. Then, cDNA library construction using mRNA extracted from the parental TOV21G cells and subsequent expression cloning were conducted. These experiments revealed that a CTL clone obtained from the bulk culture recognized a minimal epitope peptide RYEFGQALF, which was derived from an autoantigen claudin-1 presented by HLA-A*24:02 molecules. This clone exhibited cytolytic activities against three ovarian cancer cell lines and normal bronchial epithelial cells in an HLA-A*24:02-restricted manner. Our data indicate that HLA-modified cancer cells can be used as an artificial antigen-presenting cell to generate antigen-specific CTLs in a manner restricted by an HLA allele of interest. |
Databáze: | OpenAIRE |
Externí odkaz: |